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Background
Intensive Case Management (ICM) is a community-
based package of care aiming to provide long-term care 
for severely mentally ill people who do not require imme-
diate admission. ICM evolved from 2 original community 
models of care, Assertive Community Treatment (ACT) 
and Case Management (CM), where ICM emphasizes 
the importance of small caseload (fewer than 20)  and 
high-intensity input.
Objectives
To assess the effects of ICM as a means of caring for 
severely mentally ill people in the community in com-
parison with non-ICM (caseload greater than 20)  and 
with standard community care. We did not distinguish 
between models of ICM. In addition, to assess whether 
the effect of ICM on hospitalization (mean number of 
days per month in hospital) is influenced by the inter-
vention’s fidelity to the ACT model and by the rate of 
hospital use in the setting where the trial was conducted 
(baseline level of hospital use).
Search Methods
We searched the Cochrane Schizophrenia Group’s Trials 
Register (last update search April 10, 2015).
Selection Criteria
All relevant randomized clinical trials focusing on people 
with severe mental illness, aged 18 to 65 years and treated 
in the community care setting, where ICM is compared to 
non-ICM or standard care.
Data Collection and Analysis
At least 2 review authors independently selected trials, 
assessed quality, and extracted data. For binary out-
comes, we calculated risk ratio (RR) and its 95% CI, on 
an intention-to-treat basis. For continuous data, we esti-
mated mean difference (MD) between groups and its 95% 
CI. We employed a random-effects model for analyses.
We performed a random-effects meta-regression analy-
sis to examine the association of the intervention’s fidel-
ity to the ACT model and the rate of hospital use in the 
setting where the trial was conducted with the treatment 
effect. We assessed overall quality for clinically important 
outcomes using the GRADE approach and investigated 
possible risk of bias within included trials.
Main Results
The 2016 update included 2 more studies (n = 196) and 
more publications with additional data for 4 already 
included studies. The updated review therefore includes 
7524 participants from 40 randomized controlled trials 
(RCTs). We found data relevant to 2 comparisons: ICM 
vs standard care, and ICM vs non-ICM. The majority of 
studies had a high risk of selective reporting. No studies 
provided data for relapse or important improvement in 
mental state.
ICM vs Standard Care
When ICM was compared with standard care for the 
outcome service use, ICM slightly reduced the number 
of  days in hospital per month (n = 3595, 24 RCTs, MD 
−0.86, 95% CI −1.37 to −0.34, low-quality evidence, 
figure 1). Similarly, for the outcome global state, ICM 
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reduced the number of  people leaving the trial early 
(n = 1798, 13 RCTs, RR 0.68, 95% CI 0.58 to 0.79, low-
quality evidence). For the outcome adverse events, the 
evidence showed that ICM may make little or no dif-
ference in reducing death by suicide (n = 1456, 9 RCTs, 
RR 0.68, 95% CI 0.31 to 1.51, low-quality evidence). 
In addition, for the outcome social functioning, there 
was uncertainty about the effect of  ICM on unemploy-
ment due to very low-quality evidence (n  =  1129, 4 
RCTs, RR 0.70, 95% CI 0.49 to 1.0, very low-quality 
evidence).
ICM vs Non-ICM
When ICM was compared with non-ICM for the out-
come service use, there was moderate-quality evidence 
that ICM probably makes little or no difference in the 
average number of days in hospital per month (n = 2220, 
21 RCTs, MD −0.08, 95% CI −0.37 to 0.21, moderate-
quality evidence) or in the average number of admissions 
(n = 678, 1 RCT, MD −0.18, 95% CI −0.41 to 0.05, mod-
erate-quality evidence) compared to non-ICM. Similarly, 
the results showed that ICM may reduce the number of 
participants leaving the intervention early (n  =  1970, 7 
RCTs, RR 0.70, 95% CI 0.52 to 0.95, low-quality evi-
dence) and that ICM may make little or no difference in 
reducing death by suicide (n = 1152, 3 RCTs, RR 0.88, 
95% CI 0.27 to 2.84, low-quality evidence). Finally, for 
the outcome social functioning, there was uncertainty 
about the effect of ICM on unemployment as compared 
to non-ICM (n = 73, 1 RCT, RR 1.46, 95% CI 0.45 to 
4.74, very low-quality evidence).
Fidelity to ACT
Within the meta-regression we found that (1) the more 
ICM is adherent to the ACT model, the better it is at 
decreasing time in hospital (“organization fidelity” vari-
able coefficient −0.36, 95% CI −0.66 to −0.07); and (2) 
the higher the baseline hospital use in the population, the 
better ICM is at decreasing time in hospital (“baseline 
hospital use” variable coefficient −0.20, 95% CI −0.32 
to −0.10). Combining both these variables within the 
model, “organization fidelity” is no longer significant, 
but the “baseline hospital use” result still significantly 
influences time in hospital (regression coefficient −0.18, 
95% CI −0.29 to −0.07, P = .0027).
Authors’ Conclusions
Based on very low- to moderate-quality evidence, 
ICM is effective in ameliorating many outcomes rel-
evant to people with severe mental illness. Compared 
to standard care, ICM may reduce hospitalization and 
increase retention in care. It also globally improved 
social functioning, although ICM’s effect on mental 
state and quality of  life remains unclear. ICM is at 
least valuable to people with severe mental illnesses in 
the subgroup of  those with a high level of  hospitaliza-
tion (about 4  days per month in past 2  years). ICM 
models with high fidelity to the original team organi-
zation of  ACT model were more effective at reducing 
time in hospital.
However, it is unclear what overall gain ICM provides 
on top of a less formal non-ICM approach.
Fig. 1. Average number of days in hospital per month.
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We do not think that more trials comparing current 
ICM with standard care or non-ICM are justified; how-
ever, we currently know of no review comparing non-
ICM with standard care, and this should be undertaken. 
For details please see full Cochrane review.1
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